We have reason to believe that cell viability bioassays that utilise tetrazolium salts are unsuitable for assessment of islet cell viability following treatment with the cytokines IL-1 and IFN-γ. Tetrazolium salts, such as MTT and XTT, are reduced by living cells to highly coloured endproducts called formazans, and are frequently used as cell proliferation and cytotoxicity bioassays. Both MTT and XTT assays allow microplate analysis, requiring no cell transfers, and they produce a visible endpoint that can be quantified by an ELISA plate reader.
Fig. 1.
Cytokine-induced beta cell death is not paralleled by a lowered MTT/XTT reduction. Rat islets (a) and beta-TC6 cells (b) were incubated for 24 h with or without 50 U/ml of IL-1β, 1000 U/ml of IFN-γ, plus 1000 U/ml of TNF-α. The number of remaining viable cells was determined by propidium iodide staining (10 µg/ml for 15 min) followed by flow cytometry analysis. The MTT and XTT bioassays were performed using the Cell Proliferation Kits I (MTT) and II (XTT) according to manufacturer's instructions (Roche Diagnostics, Mannheim, Germany). The viability of the treated cells is expressed as a percentage of that of the control cells not exposed to cytokines. The data points show the means ± SEM for three independent experiments. * p<0.05 vs control cells; ** p<0.01 vs control cells using the Student's t test
